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OPEN
ORIGINAL ARTICLE
The use of statins for the treatment of depression in patients
with acute coronary syndrome
SW Kim1, KY Bae1, JM Kim1, IS Shin1, YJ Hong2, Y Ahn2, MH Jeong2, M Berk3,4 and JS Yoon1
This study aimed to investigate the effect of statins for the treatment of depression in individuals with acute coronary syndrome
(ACS). We used 1-year follow-up data of a 24-week double-blind, placebo-controlled trial of escitalopram and a naturalistic
prospective observational cohort study. Of 446 participants with comorbid depressive disorders and ACS at baseline, 300
participated in a randomised escitalopram trial and the remaining 146 participated in a naturalistic observational study. The
participants in the two studies were approached for a 1-year follow-up investigation. Treatment response rates, deﬁned as a ⩾ 50%
reduction in the Hamilton Depression Rating Scale (HAM-D) and Beck Depression Inventory (BDI) scores, were used as the outcome
variables. In the escitalopram trial, both HAM-D and BDI response rates were highest in patients taking escitalopram and statins
together and lowest in patients receiving neither medication. Logistic regression analyses revealed that statin use was signiﬁcantly
associated with higher response rates on both the HAM-D and BDI at 1 year, whereas no such associations were found for
escitalopram. In the naturalistic observational study, the response rates at 1 year did not differ signiﬁcantly by statin use. Instead,
the HAM-D response rate was signiﬁcantly higher in patients taking lipophilic statins than in those who did not. In conclusion,
statins may be effective for the treatment of depression independent of medical status and escitalopram use, and they may
potentiate the antidepressant action of serotonergic antidepressants in patients with ACS.
Translational Psychiatry (2015) 5, e620; doi:10.1038/tp.2015.116; published online 18 August 2015
INTRODUCTION
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors) are widely used for primary and secondary prevention of
cardiovascular disease by treating hypercholesterolaemia. Low
mood and suicide have been reported as possible side effects of
cholesterol-lowering treatment with statins.1 The association
between lower cholesterol and depression/suicide was been
hypothesised as being related to reduced serotonin in the brain.2
Nevertheless, a more recent meta-analysis3 of randomised
controlled trials demonstrated no adverse effects of statins on
psychological outcomes, and a systemic review and meta-
analysis4 of observational studies suggested that statin use might
be associated with lower risk of depression. Furthermore, a few
studies suggested that statins have an antidepressant effect5
independent of cholesterol-lowering effects.6 To date, only two
small randomised controlled trials of statins has been published,
suggesting antidepressant properties adjunctive to serotonin
reuptake inhibitors in the general population with major
depressive disorder.7,8
The inﬂammatory hypothesis of depression is now well
established,9,10 and statins have known effects on inﬂammatory
cytokines, and also reduce oxidative stress markers.11 Statins exert
anti-inﬂammatory activity, including reducing C-reactive protein
concentration in both healthy individuals and those with stable
vascular disease.12 In patients who experience an acute cardiac
event, statins induce a rapid reduction in tumour necrosis factor
alpha and interferon gamma production in stimulated T-lympho-
cytes, and inhibit the T helper cell (Th-1) immune response.13 In
human hepatocytes, statins reduce interleukin-6-induced
expression of C-reactive protein, suggesting a hepatic source of
its anti-inﬂammatory effects.14 Furthermore, the low-density
lipoprotein cholesterol-lowering effect of statins may be asso-
ciated with anti-inﬂammatory effects, because low-density lipo-
protein cholesterol itself strongly promotes inﬂammation.15 These
anti-inﬂammatory effects and antioxidant effects of statins are
thought to be associated with antidepressant effects.11,16
However, studies demonstrating the effects of statins on
depression in individuals with acute coronary syndrome (ACS;
that is, any condition brought on by sudden reduced blood ﬂow
to the heart, including myocardial infarction or unstable angina)
are limited. In addition, to our knowledge, no previous reported
study exists that identiﬁes the interaction between statins and
serotonin reuptake inhibitors on antidepressant effects in
individuals with ACS. This study aimed to investigate the effects
of statins on depression in a Korean population with ACS. We used
1 year follow-up data of a 24-week double-blind, placebo-
controlled trial of escitalopram for treatment of depressive
disorder in patients with ACS (Escitalopram for DEPression in
ACS, EsDEPACS)17 and a naturalistic prospective observational
cohort study (Korean DEPression in ACS, K-DEPACS).18
MATERIALS AND METHODS
Study design and participants
The present study included subjects with comorbid ACS and depression at
baseline in the K-DEPACS study. The K-DEPACS study is a naturalistic
prospective cohort study that began in 2006. Comprehensive study details
have been published previously.17,18 Participants were recruited from
1Department of Psychiatry, Chonnam National University Medical School, Gwangju, Korea; 2Department of Cardiology, Chonnam National University Medical School, Gwangju,
Korea; 3IMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, VIC, Australia and 4Department of Psychiatry, The University of Melbourne, Parkville,
VIC, Australia. Correspondence: Dr JM Kim, Department of Psychiatry, Chonnam National University Medical School, 160 Baekseoro, Donggu, Gwangju 501-746, Korea.
E-mail: jmkim@chonnam.ac.kr
Received 6 February 2015; revised 26 June 2015; accepted 8 July 2015
Citation: Transl Psychiatry (2015) 5, e620; doi:10.1038/tp.2015.116
www.nature.com/tp
those patients 2–14 weeks after an ACS episode that had been conﬁrmed
by various examinations and that resulted in hospitalisation (n= 4809) in
the central coordinating centre of the Korea Acute Myocardial Infarction
Registry.
Patients who met the eligibility criteria and agreed to participate
(n=1152) were screened for depressive symptoms using the Beck
Depression Inventory (BDI).19 Those with a score indicative of depression
(410) underwent a structured diagnostic evaluation conducted by
research psychiatrists using the Mini-International Neuropsychiatric
Interview,20 which categorises patients as having depressive disorder. Of
them, 446 (38.7%) who met the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV)21 criteria for major or minor depressive
disorder were subjects in the present study. Of these, 300 (67.3%)
participated in the EsDEPACS trial, which was a 24-week, double-blind
randomised controlled trial of escitalopram (ClinicalTrials.gov registry
number: NCT00419471). The remaining 146 individuals with depression
did not participate in the clinical trial and only received standard medical
treatment (K-DEPACS cohort). All participants in the two studies were
approached for 1-year follow-up investigation. Written informed consent
was obtained from all participants. Both studies were approved by the
Chonnam National University Hospital Institutional Review Board.
In total, 300 patients from the EsDEPACS trial were randomised to either
escitalopram (n=149) or placebo (n=151). Statins were prescribed
according to medical indications as determined by the treating
cardiologists (n= 226). To identify the effects of statins and interactions
between statins and escitalopram, the 300 participants of the EsDEPACS
trial were divided into four groups according to escitalopram and statin
use, as follows: use of both escitalopram and statins (Combination: n= 116,
38.7%), Escitalopram only (subjects who were administered escitalopram
but were not prescribed a statin, n= 33, 11.0%), Statin only (subjects who
were prescribed a statin but were not administered escitalopram, n= 110,
36.7%) and No medication (subjects who were not administered
escitalopram or a statin and received standard medical treatment only,
n= 41, 13.7%) (Figure 1). A total of 213 patients (71.0%) completed a 1-year
follow-up evaluation, with no signiﬁcant differences in follow-up rates
among the four groups (Combination 75.9%, Escitalopram only 57.6%,
Statin only 70.9%, No medication 68.3%; P=0.225).
Among 146 participants who had depression in the K-DEPACS cohort
study, 97 (66.4%) patients received a statin (statin group) and 49 (33.6%)
patients received standard medical treatment only (no-medication group).
A total of 111 subjects (76.0%) completed a 1-year follow-up evaluation,
with no signiﬁcant differences in follow-up rates among the two groups
(Statin 75.3% and No medication 77.6%, P=0.759).
Measures
The primary outcome measure in the EsDEPACS trial and the K-DEPACS
cohort study was the 17-item Hamilton Depression Rating Scale (HAM-D).22
The BDI was selected as a secondary outcome measure in the
present study.
Various cardiac risk factors and medical status were investigated. Fasting
total cholesterol level was assayed; hypercholesterolaemia was diagnosed
when the cholesterol level was4200mg dl− 1 or if patients had a history of
ongoing hyperlipidemia treatment. Body mass index was calculated, and
participants were categorised as obese in cases of body mass index
425 kg/m2. To evaluate current cardiac status, diagnoses of myocardial
infarction or unstable angina were made. ACS severity was estimated
(range: I–IV) using the Killip classiﬁcation.23 Left ventricular ejection
fraction was estimated using echocardiography. Serum troponin I was
measured as a cardiac biomarker.
Study procedures
The details of the EsDEPACS trial have been published, in which superior
effects of escitalopram to placebo were found.17 In brief, subjects were
randomised to the escitalopram and placebo conditions in a 1:1 ratio
following computer-generated randomisation codes. Flexible doses of
study medications ranging from 5 to 20mg were administered for
24 weeks by a blinded psychiatrist. The mean (s.d.) doses at the last visit
were 7.6 (3.7) mg for the escitalopram group and 8.5 (3.9) mg for the
placebo group, and the mean (s.d.) treatment durations were 19.8 (3.2) and
19.7 (3.3) weeks, respectively.
Concomitant medications, such as any other antidepressant, psycho-
stimulant, antipsychotic or anticholinergic agents, were not permitted. In
the K-DEPACS cohort, standard medical treatments were provided to all
subjects by the study cardiologists based on international guidelines for
the management of ACS. Outcome measures were blindly assessed
following the prescription of statins as well as escitalopram.
Statistical analyses
The main analyses were performed on an intent-to-treat basis, including all
patients who were randomly assigned to treatment. Demographic and
clinical characteristics at baseline were compared according to treatment
condition using χ2-tests, analysis of variance or independent t-tests.
Treatment response rates at 1 year, deﬁned as a ⩾ 50% reduction in the
HAM-D or BDI baseline score, were used as primary outcome variables.
Response rates were also calculated at 24 weeks in the EsDEPACS trial.
Response rates among the groups were compared using χ2-tests.
Figure 1. Flow diagram for recruitment and grouping according to treatment status. ACS, acute coronary syndrome; Esc., escitalopram; EsDEPACS,
the Escitalopram for Depression in Acute Coronary Syndrome trial; K-DEPACS, the Korean Depression in Acute Coronary Syndrome study.
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Proportions of participants who no longer met DSM-IV criteria for major or
minor depressive disorder at 1 year among the groups were also
compared using χ2-tests. Repeated-measures analysis of variance treating
time as the within-subject factor and treatment group as the between-
subjects factor demonstrated changes in HAM-D and BDI scores over time
in the EsDEPACS trial after adjusting for baseline scores. Logistic regression
models were used to investigate independent effects of escitalopram and
statins on treatment response after adjusting for baseline score of the
depression measure, demographic and clinical characteristics that were
not equally distributed among the groups (Po0.1) in unadjusted analyses,
key cardiac parameters (myocardial infarction, Killip class and total
cholesterol level) and for each drug (escitalopram and statins). In the
EsDEPACS trial, 41 subjects randomly assigned to the escitalopram group
discontinued the trial immediately after their baseline visit. Therefore,
exploratory regression analyses of the 1-year follow-up evaluations
excluded these subjects, who may have shown no medication effects.
Another exploratory analyses were conducted to compare differential
effects according to statin type: lipophilic statins (simvastatin, atorvastatin,
lovastatin and pitavastatin) versus hydrophilic statins (rosuvastatin and
pravastatin).24 A P-value o0.05 (two tailed) was taken to indicate statistical
signiﬁcance, and statistical analyses were performed using the SPSS
software (ver. 21.0; SPSS, Chicago, IL, USA).
RESULTS
Baseline characteristics by treatment status are compared in
Table 1. No signiﬁcant differences in demographic or clinical
characteristics, except for the prevalence of obesity, were found
among the four groups in the EsDEPACS trial. Prevalence of
hypertension and serum cholesterol levels tended to be different
among the groups, but the differences were not statistically
signiﬁcant (P= 0.091 and 0.090, respectively). In the K-DEPACS
cohort, serum levels of troponin-I and total cholesterol were
signiﬁcantly higher in the statin-only group than in the no-
medication group.
Analysis of the EsDEPACS trial
In the EsDEPACS trial, HAM-D and BDI response rates at both
24 weeks and 1 year differed signiﬁcantly among treatment
groups (Figure 2). Both HAM-D and BDI response rates at 24 weeks
and 1 year were highest in patients taking escitalopram and
statins together and lowest in patients receiving neither medica-
tion. Proportion of participants who no longer met DSM-IV criteria
for major or minor depressive disorder at 1 year was also highest
in the combined treatment group, but differences among
treatment groups were not statistically signiﬁcant (Combination
65.9%, Escitalopram only 52.6%, Statin only 50.0%, No medication
42.9%; χ2= 6.691, P= 0.082).
In the logistic regression, statin use was signiﬁcantly associated
with higher response rates on both the HAM-D and BDI at 1 year,
whereas escitalopram use was not associated with the response
rates on the HAM-D and BDI at 1 year after adjusting for signiﬁcant
covariates (Table 2). However, escitalopram was signiﬁcantly
Table 1. Baseline characteristics by treatment status in all depressive patients after ACS (n= 446)
EsDEPACS trial (N= 300) K-DEPACS cohort (N= 146)
Esc.+Statin Esc. only Statin only Placebo only P-value Statin use Standard treatment P-value
N (%) N (%) N (%) N (%)
116 (38.7) 33 (11.0) 110 (36.7) 41 (13.7) 97 (66.4) 49 (33.6)
Demographic characteristics
Age, mean (s.d.) years 60.3 (10.8) 58.9 (12.9) 60.4 (10.8) 59.3 (10.0) 0.855 57.8 (11.8) 59.3 (11.2) 0.458
Gender, N (%) men 66 (56.9) 22 (66.7) 63 (57.3) 30 (73.2) 0.223 59 (60.8) 25 (51.0) 0.258
Education, mean (s.d.) years 9.2 (4.3) 10.1 (3.7) 9.0 (4.2) 9.6 (3.8) 0.616 8.9 (5.4) 9.0 (4.5) 0.891
Depression characteristics
HAM-D, mean (s.d.) score 15.6 (4.7) 16.8 (5.1) 15.9 (5.0) 14.9 (4.1) 0.374 10.7 (3.5) 11.3 (3.4) 0.327
BDI, mean (s.d.) score 18.5 (8.3) 20.0 (8.5) 19.2 (7.8) 19.1 (7.3) 0.782 14.0 (7.2) 14.5 (5.5) 0.650
DSM-IV diagnosis, N (%)
Major depressive disorder 63 (54.3) 22 (66.7) 59 (53.6) 25 (61.0) 0.511 18 (18.6) 15 (30.6) 0.100
Cardiac risk factors, N (%)
Hypertension 64 (55.2) 26 (78.8) 70 (63.6) 24 (58.5) 0.091 43 (44.3) 25 (51.0) 0.444
Diabetes mellitus 33 (28.4) 11 (33.3) 31 (28.2) 10 (24.4) 0.868 18 (18.6) 10 (20.4) 0.788
Hypercholesterolaemia 61 (52.6) 12 (36.4) 54 (49.1) 17 (41.5) 0.318 57 (58.8) 21 (42.9) 0.069
Obesity 46 (39.7) 13 (39.4) 55 (50.0) 10 (24.4) 0.038 42 (43.3) 18 (36.7) 0.447
Current smoker 33 (28.4) 10 (30.3) 28 (25.5) 14 (34.1) 0.754 34 (35.1) 10 (20.4) 0.069
Current cardiac status
ACS diagnosis, N (%)
Myocardial infarction 77 (66.4) 15 (45.5) 70 (63.6) 22 (53.7) 0.111 31 (32.0) 21 (42.9) 0.194
Killip class 41, N (%) 20 (17.2) 4 (12.1) 28 (25.5) 7 (17.1) 0.248 18 (18.6) 10 (20.4) 0.788
LVEF, mean (s.d.) % 60.7 (10.6) 59.4 (12.3) 60.4 (11.4) 62.3 (12.0) 0.561 59.1 (12.2) 62.0 (13.1) 0.190
Troponin I, mean (s.d.) mg dl− 1 10.0 (9.0) 8.6 (6.4) 10.2 (8.6) 8.2 (5.7) 0.481 11.3 (17.4) 6.2 (12.2) 0.043
CK-MB, mean (s.d.) mg dl− 1 17.5 (23.0) 16.1 (18.3) 17.0 (21.7) 14.5 (18.3) 0.888 20.1 (47.4) 15.8 (29.8) 0.570
T-cholesterol 184.3 (38.0) 171.3 (42.6) 188.6 (39.8) 175.4 (43.8) 0.090 195.4 (38.4) 180.6 (47.8) 0.045
CRP 1.1 (0.9) 1.2 (1.1) 1.4 (3.2) 0.7 (0.3) 0.303 1.0 (1.1) 1.2 (2.7) 0.480
Abbreviations: ACS, acute coronary syndrome; BDI, Beck Depression Inventory; CK-MB, creatine kinase-MB; CRP, C-reactive protein; DSM-IV, Diagnostic and
Statistical Manual of Mental Disorders 4th edition; Esc., escitalopram; EsDEPACS, the Escitalopram for Depression in Acute Coronary Syndrome trial; HAM-D,
Hamilton Depression Rating Scale; K-DEPACS, the Korean Depression in Acute Coronary Syndrome study; LVEF, left ventricular ejection fraction; T-cholesterol,
total cholesterol. Values in bold show statistical signiﬁcance (P-value= 0.05).
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Figure 2. Response rates at 24 weeks and 1 year according to treatment status in the EsDEPACS trial and K-DEPACS cohort. (a) EsDEPACS trial
sample. HAM-D and BDI response rates at both 24 weeks and 1 year differed signiﬁcantly among treatment groups (P= 0.018, 0.045, 0.008 and
0.017, respectively). (b1) K-DEPACS cohort sample. HAM-D and BDI response rates at 1 year did not differ signiﬁcantly according to statin use
(P= 0.388 and 0.773, respectively). (b2) K-DEPACS cohort sample. HAM-D and BDI response rates at 1 year were signiﬁcantly higher in patients
who took lipophilic statins than in those who took hydrophilic statins (P= 0.011 and 0.042, respectively). BDI, Beck Depression Inventory; Esc.,
escitalopram; EsDEPACS, the Escitalopram for Depression in Acute Coronary Syndrome trial; HAM-D, Hamilton Depression Rating Scale;
K-DEPACS, the Korean Depression in Acute Coronary Syndrome study; Med., medication.
Table 2. Logistic regression analysis of response status by statin and escitalopram use in the EsDEPACS trial
HAM-D response (1 year) BDI response (1 year) HAM-D response (24 weeks) BDI response (24 weeks)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
ITT set
Statin use 2.23 (1.11–4.51) 0.025 2.82 (1.35–5.90) 0.006 1.81 (0.94–3.50) 0.078 1.74 (0.89–3.41) 0.108
Escitalopram use 1.57 (0.90–2.75) 0.111 1.40 (0.79–2.49) 0.250 2.18 (1.23–3.85) 0.007 2.55 (1.43–4.55) 0.002
Efﬁcacy set
Statin use 2.84 (1.32–5.87) 0.005 3.32 (1.57–7.05) 0.002 NA NA
Escitalopram use 2.35 (1.29–4.31) 0.006 1.88 (1.02–3.47) 0.044
Abbreviations: BDI, Beck Depression Inventory; CI, conﬁdence interval; EsDEPACS, the Escitalopram for Depression in Acute Coronary Syndrome trial; HAM-D,
Hamilton Depression Rating Scale; ITT, intention-to-treat; NA, not applicable; OR, odds ratio. Adjusted for baseline score of depressive measure, obesity,
hypertension, total cholesterol level, myocardial infarction diagnosis, Killip class and each use of statin and escitalopram. The efﬁcacy set group excluded
subjects who were randomly assigned to the escitalopram arm but discontinued the trial immediately after the baseline visit. Values in bold show statistical
signiﬁcance (P-value= 0.05).
Figure 3. Adjusted mean Hamilton Rating Scale for Depression (HAM-D) and Beck Depression Inventory (BDI) scores over time in the
EsDEPACS trial. (a) Statistics for group by time interaction after adjustment for baseline HAM-D score are F= 2.839 and P= 0.010. (b) Statistics
for group by time interaction after adjustment for baseline BDI score are F= 2.357 and P= 0.030. Esc., escitalopram; EsDEPACS, the
Escitalopram for Depression in Acute Coronary Syndrome trial; Med., medication.
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associated with higher response rates on both the HAM-D and BDI
at 24 weeks, whereas statin use was not signiﬁcantly associated
with these outcomes at 24 weeks. When we excluded from the
analysis subjects who were randomly assigned to receive
escitalopram but who discontinue the clinical trial after the ﬁrst
visit, both statin and escitalopram use were found to be
signiﬁcantly associated with higher response rates on the HAM-D
and BDI at 1 year.
Figure 3 illustrates changes in HAM-D and BDI scores over time
according to group. There was a signiﬁcant time× group
interaction for both the HAM-D and BDI scores (P= 0.010 and
0.030, respectively). Similar to the response-rate analyses, HAM-D
and BDI scores were most improved in patients taking escitalo-
pram and statins together.
Escitalopram as a study medication was not provided to
subjects after the 24-week trial period. Escitalopram was being
taken by eight patients at the 1-year follow-up point on the basis
of clinician’s judgment. However, antidepressant use at 1 year did
not differ signiﬁcantly among the groups. Furthermore, the results
were not changed substantially when the same analyses were
repeated after excluding these participants.
Exploratory analyses were conducted to compare the efﬁcacy of
lipophilic statins (n= 141) and hydrophilic statins (n= 85), as the
former theoretically have greater brain permeability. In the
EsDEPACS trial, there was no signiﬁcant difference in HAM-D or
BDI response rates between these two groups (all P40.1).
Safety results were reported in our previous study.17 In brief,
dizziness was more frequently reported in patients taking
escitalopram compared with those who did not take it (13.9 vs
4.6%, P= 0.018). However, there were no signiﬁcant differences
with respect to any other adverse events according to use of
escitalopram or statin.
Analysis of the K-DEPACS cohort
HAM-D and BDI response rates at 1 year did not differ signiﬁcantly
according to statin use (Figure 2). Proportions of participants who
no longer met DSM-IV criteria for major or minor depressive
disorder at 1 year were not signiﬁcantly different between the two
groups (Statin 52.1% and No medication 44.7%, χ2 = 0.535,
P= 0.464). Logistic regression analysis also demonstrated no
signiﬁcant association between statin use with HAM-D or BDI
response rates (Table 3). Antidepressants were being taken by
only two patients, who were in the no-medication group, at the
1-year follow-up point. When the same analyses were repeated
after excluding them, the results were not substantially changed.
In the K-DEPACS cohort, HAM-D and BDI response rates were
signiﬁcantly higher in patients who took lipophilic statins (n= 52)
than in those who took hydrophilic statins (n= 45) (44.7 vs 17.1%
and 42.1 vs 20.0%, respectively). No demographic or clinical
characteristic differed signiﬁcantly between the lipophilic and
hydrophilic statins groups. Patients receiving hydrophilic statins
were more likely to have diabetes (26.7% vs 11.5%, P= 0.056).
Logistic regression analysis was conducted to investigate the
independent effects of lipophilic statins compared with hydro-
philic statins after adjusting for baseline score of depression
measure and clinical status (diabetes, total cholesterol level, type
of ACS and Killip classiﬁcation) (Table 3). Patients receiving
lipophilic statins were signiﬁcantly more likely to achieve HAM-D
response at 1 year compared with those receiving hydrophilic
statins, after adjusting for these variables. Lipophilic statin use was
also associated with higher BDI response at 1 year compared with
hydrophilic statin use, but it was only a trend in a multivariate
analysis (P= 0.054). When subjects were divided into two groups
according to use of lipophilic statins, patients who took lipophilic
statins (n= 52) were signiﬁcantly more likely to achieve HAM-D
response at 1 year than those who did not (no-medication and
hydrophilic statin group, n= 94).
DISCUSSION
Although there are a few studies suggesting beneﬁcial effects of
statins on depression in the general population, studies demon-
strating antidepressant effect of statins in individuals with ACS are
limited. The present study showed improvement in depressive
symptoms associated with statin use in individuals with ACS and
depressive disorder. These effects of statins at the 1-year follow-up
point were independent of medical status and escitalopram use.
However, in both subjective and objective measures, response
rates in the group receiving combined statin and escitalopram
treatment were highest among the four groups. To our knowl-
edge, this is the ﬁrst reported study to demonstrate an
antidepressant effect of statins and an interaction between statins
and escitalopram in individuals with ACS and depression.
The pathophysiology and aetiology of depression are hetero-
geneous and complex. Monoamine deﬁciency was hypothesised
to be the main cause of depression, and medications to
compensate for this deﬁciency have been most widely used for
the treatment of depression. However, the monoaminergic theory
of depression has failed to deliver novel agents beyond the
limited treatment options currently available.25 Inﬂammation,
oxidative stress and stress reactions have also recently been
suggested operative neurobiological pathways in depression.26 A
growing body of literature illustrates the presence of increased
inﬂammatory biomarkers, including inﬂammatory cytokines, in
patients with depression.27 However, medications mainly target-
ing inﬂammatory and oxidative pathways have not been widely
used in clinical settings. Our results are in accordance with
previous novel clinical trials suggesting antidepressant effects of
anti-inﬂammatory agents such as celecoxib, pioglitazone and
N-acetylcysteine.28–31 Furthermore, ﬁndings of the highest
response rate in the combination of escitalopram and statin
group (escitalopram use for 24 weeks and statin use for 1 year)
suggests that statins may potentiate the efﬁcacy of serotonergic
antidepressants. This result is in accordance with a few recent
controlled trials showing that augmentation of statins (lovastatin
and atorvastatin) to serotonin reuptake inhibitors (ﬂuoxetine and
Table 3. Logistic regression analysis of response status by statin use in the K-DEPACS cohort
HAM-D response (1 year) BDI response (1 year)
OR (95% CI) P-value OR (95% CI) P-value
Statin use vs no use 1.19 (0.45–3.18) 0.726 0.89 (0.36–2.22) 0.798
Lipophilic statin use vs hydrophilic statin use 3.91 (1.21–12.59) 0.022 2.97 (0.98–9.00) 0.054
Lipophilic statin use vs all others 2.91 (1.21–6.99) 0.017 2.00 (0.86–4.66) 0.108
Abbreviations: BDI, Beck Depression Inventory; CI, conﬁdence interval; HAM-D, Hamilton Depression Rating Scale; K-DEPACS, the Korean Depression in Acute
Coronary Syndrome study; OR, odds ratio. Adjusted for baseline score of depression measure, diabetes, total cholesterol level, type of acute coronary
syndrome and Killip classiﬁcation. Values in bold show statistical signiﬁcance (P-value= 0.05).
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citalopram) may be effective for treating depression in the general
population with major depressive disorder.7,8
In the intention-to-treat population of this study, the effect of
escitalopram treatment on depressive symptoms was not
observed at the 1-year follow-up point. This might be attributed
to high proportions of subjects who had discontinued clinical trial
after baseline visit. In fact, effect of escitalopram was seen at
1-year follow-up when the analysis was conducted in subjects
who received escitalopram for at least 4 weeks. Given that almost
all subjects had discontinued escitalopram at 24 weeks when the
clinical trial was completed, and given that the mean duration of
escitalopram treatment was about 20 weeks in the EsDEPACS trial,
it appears that the effects of escitalopram use persist over a long
period of time in patients with ACS. Our ﬁndings also suggest
potential maintenance effects of the statin on depression. In some
populations with ACS, escitalopram use may be limited due to its
potential to increase the risk of bleeding or QTc interval
prolongation.32,33 In this case, statins may be a novel alternative
to treat depression or maintain the antidepressant effects of a
serotonin reuptake inhibitor.
In contrast to the results of clinical trial sample, statin use was
not effective for the treatment of depression in the naturalistic
observational study sample. This difference in result may be
attributed to interactions of statin use with escitalopram as well as
the placebo, which can biologically modulate the release of
opioids, dopamine, serotonin and immune mediators.34 In
addition, the clinical trial sample regularly met a psychiatrist for
24 weeks but subjects in the naturalistic observational study
did not.
In addition, residual confounding in non-randomised trials is an
important factor. The factors that drive statin prescription are
known risk factors for depression. These data, as well as multiple
other studies, suggest that obesity is a risk factor for depression.
There is also extensive data that a poor-quality diet is a risk factor
for depression,35 as is physical inactivity.36 These factors drive
statin prescription, together with other risk factors for cardiovas-
cular disease such as smoking, which itself is a risk factor for
depression.37 As a consequence, one could reasonably expect
participants prescribed statins to actually be at a considerably
higher risk of depression. As a consequence, it is entirely feasible
that the null ﬁnding in the non-randomised study, at least in part,
reﬂects these factors. In addition, because of this residual
confounding, non-randomised trials are likely to underestimate
the antidepressant effects of statins.
There are two distinct types of statin, when classiﬁed by their
lipophilicity. Lipophilic statins and hydrophilic statins exert
differential effects on the human body.24,38–40 In the naturalistic
observational study sample, the response rates with hydrophilic
statins were signiﬁcantly lower than those of lipophilic statins,
which were similar to those with statins in the clinical trial sample.
The relatively high response rates with hydrophilic statins used in
the clinical trial sample, which resulted in the absence of a
difference in effects according to the type of statins, may be also
attributable to interactions with escitalopram and the placebo
effect. The reason for the greater effect of lipophilic statins is
unclear. The degree of lipophilicity required to pass the blood–
brain barrier may be associated with direct effects on the brain.
Speciﬁcally, lipophilic statins are more likely to cross the blood–
brain barrier than are hydrophilic statins.41 In addition, lipophilic
statins enter cells by passive diffusion and are thus widely
distributed in different tissues, whereas hydrophilic statins are
more liver-speciﬁc and are taken up via carrier-mediated
mechanisms, thus reducing their ability to exert non-lipid effects
in extrahepatic tissues.41
This study has some limitations. First, we should be cautious of
generalising the antidepressant effects of statins to the general
population, because this study was conducted only in individuals
with ACS. Second, psychological treatment effects were not fully
controlled in the clinical trial when patients met a psychiatrist who
prescribed study medications. Third, the severity of our partici-
pants’ depression was relatively low compared with that of
patients in other clinical trials of depression; further study is
warranted to investigate whether statins are effective in popula-
tions with severe depression. Fourth, the escitalopram-only group
contained a relatively small number of subjects compared with
the other groups. Furthermore, the study design combined a
randomised controlled trial with a naturalistic observational study.
Therefore, statins were administered to the subjects by cardiol-
ogists without randomisation, whereas administration of escitalo-
pram was randomised; as mentioned above, this residual
confounding may underestimate the effects of statins. However,
depression assessments were conducted blind, independent of
statin use. Further study should include randomisation of both
escitalopram and statin to improve statistical power and remove
residual confounding.
In conclusion, the results of this study suggest that statins may be
effective for the treatment of depression independent of medical
status and escitalopram use, and they may potentiate the
antidepressant action of serotonergic antidepressants in patients
with ACS. In some patients with ACS and depressive disorder who are
not tolerant to antidepressants, statins may be a novel alternative.
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